Business Context and Reporting Period
This Form 8-K is a current report filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on January 5, 2018, regarding events occurring on January 3, 2018. The registrant is a Delaware corporation headquartered in Boulder, Colorado, and is classified as an emerging growth company.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors unanimously voted to increase its size to eight members.
- New Director Appointment: Arlene M. Morris was elected as a director to fill the newly created seat, effective immediately. She is classified as an independent director under NASDAQ Capital Market rules.
- Compensation Structure: Ms. Morris will receive annual cash compensation of $35,000, with the option to receive all or part of this amount in restricted common stock or stock options.
- Equity Grant: Ms. Morris received a one-time initial option grant to purchase 24,000 shares of common stock at the fair market value on January 3, 2018. These options vest in 36 equal monthly installments.
Outlook, Risks, and Management Commentary
Management highlighted Ms. Morris's extensive industry experience, including prior roles as CEO of Syndax Pharmaceuticals and Affymax, Inc., and current board memberships at Viveve Medical, Palatin Technologies, and Neovacs, SA. The filing states there are no related person transactions or undisclosed arrangements regarding her election. No specific financial guidance, risks, or contingencies were disclosed in this report.
Key Facts for Investor Verification
- Verify the exact number of outstanding shares and the impact of the 24,000-share option grant on potential dilution.
- Confirm the vesting schedule details for the initial option grant (36 monthly installments).
- Review the attached press release (Exhibit 99.1) for additional context on the strategic rationale for the board expansion.
- Note that the filing text does not provide a clear value for the company's current cash position or burn rate.